AN2 Therapeutics director Robin Shane Readnour disposes of 1,108 common shares worth $6,675 - ANTX News | RalliesAN2 Therapeutics director Robin Shane Readnour disposes of 1,108 common shares worth $6,675
A
ANTX• Director reports indirect share sales
- Director Robin Shane Readnour reported indirect sales of 1,108 AN2 Therapeutics common shares on Sep. 9, 2026.
- The transactions were priced at a weighted average of $6.02 per share.
- Indirect beneficial ownership was reported at 557,467 shares and 624,765 shares following the sales.
•
